B+
Bull case
25%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
RCKT
RocketDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The October update clarified an FDA-aligned 12-patient RP-A501 pivotal population and reported preliminary safety observations in three modified-protocol patients. The initial loan funding extends Rocket's stated operating runway into the third quarter of 2028, supporting trial execution [#IR-2026-10-07] [#IR-2026-10-06].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
KRESLADI onboarding, reimbursement and commercial uptake are not yet established by the packet [#SEC-8K-2026-08-10].
Momentum
52
Value
59
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.90 · Bull $3.20 · Bear $0.80Analysis 2026-10-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.58
Why
Momentum52 · Δ7d +3.3
Value59 · Δ7d +0.1
Sentiment37 · Δ7d +6.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.1.
Contradictions & invalidation
- • KRESLADI onboarding, reimbursement and commercial uptake are not yet established by the packet [#SEC-8K-2026-08-10].
- • Only $35 million of the up-to-$150 million credit facility was initially funded; conditional draws, floating interest, covenants and debt service limit financing flexibility [#8-K-2026-10-06].
- • The Danon efficacy readout remains targeted for mid-2028.
Catalyst clock
2026-12-31
RP-A601 pivotal-study regulatory update
Lead driver: Value · See fundamentals
Momentum
52
8% active weight
Current posture
7d trendImproving
Δ7d
+3.3
Δ21d
-15.7
Value
59
47% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+17.7
Sentiment
37
45% active weight
Current posture
7d trendImproving
Δ7d
+6.5
Δ21d
+18.4
Why this grade
Composite grade D. Momentum 52.0 / Value 58.7 / Sentiment 37.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-17. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.90
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$250.29M
Beta
0.48
Shares Out
109.78M
P/E (TTM) · Derived
-1.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.50
Rev YoY
-
EPS YoY
-273.3%
Gross Margin
-
Op Margin
-
Net Debt
-$164.05M
Current Ratio
9.24
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data